Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Researchers develop imaging procedure to diagnose Alzheimer’s

A type of molecular imaging procedure may be capable of detecting the presence of beta-amyloid, a protein which is linked to Alzheimer's disease, according to preliminary research conducted by Avid Radiopharmaceuticals.

For the study, researchers used florbetapir F 18 – a diagnostic chemical that binds to beta-amyloid, along with positron emission tomography (PET) scanners.

Florbetapir-PET imaging was conducted on 35 patients near the end of their lives and this was compared with the beta-amyloid levels that were determined by autopsy after their death.

An analysis of images and other data indicated a correlation between florbetapir-PET images and the levels of beta-amyloid pathology at autopsy.

In addition, the Florbetapir-PET scans matched the autopsy results 96% of the time.

The authors noted that the study provides evidence that a molecular imaging procedure can identify beta-amyloid pathology in the brains of individuals during life, a development which can help identify Alzheimer’s disease.